The Claim
Liraglutide, through GLP-1 receptor agonism, directly improves insulin sensitivity and glucose control in individuals with obesity and prediabetes within two weeks, independent of weight loss, and these effects are abolished by GLP-1 receptor antagonism.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Liraglutide enhances the body's ability to use insulin and regulate blood glucose in people with obesity and prediabetes within two weeks, even without weight loss, and blocking GLP-1 receptors eliminates these effects.
See the scientific wording
GLP-1 receptor agonism by liraglutide directly improves insulin sensitivity and glucose control in individuals with obesity and prediabetes within two weeks, independent of weight loss, and these effects are abolished by GLP-1 receptor antagonism.
Liraglutide binds to GLP-1 receptors on pancreatic cells, which stops the liver from releasing too much sugar and makes muscle and fat tissue more responsive to insulin. This lowers blood sugar quickly, even before any weight loss happens. Blocking these receptors reverses the effect.
What the research says
1 studyThis study shows that a drug called liraglutide helps the body use insulin better and lowers blood sugar in just two weeks—even before people lose weight—and when scientists blocked the drug’s target, those benefits disappeared. So yes, it works exactly as claimed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.